Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.